Please login to the form below

Not currently logged in
Email:
Password:

immune disease

This page shows the latest immune disease news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

researchers’time). Many of the proposed projects address brain disorders, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, major depression, and immune-mediated diseases such as Crohn’s

Latest news

More from news
Approximately 1 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Pharma deals in July 2015 Pharma deals in July 2015

    cCAM is developing an immune checkpoint protein belonging to the Human CEA (Carcino-Embryonic Antigen) protein family. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    658. Avalanche / Regeneron. Development and commercialisation licence. Gene therapy products for ophthalmologic disease. ... MGD010, a preclinical bispecific antibody for treatment of auto-immune disease. 502.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Immuno-oncology. One area of interest for many pharma companies is the potential for immunotherapies - drugs that encourage the body's immune system to tackle a disease. ... or with other agents that might affect a different part of the immune system, or

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics